Literature DB >> 16683990

The pharmacokinetics of coagulation factors.

M Lee1, M Morfini, C Negrier, V Chamouard.   

Abstract

In this article, we provide a summary of the generally accepted approaches to the design and analysis of studies examining the pharmacokinetic (PK) profile of an infused coagulation factor in patients with a deficiency of one or more of these factors. Furthermore, we briefly review the known PK results for various commercially available coagulation factor preparations under single and continuous infusion.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16683990     DOI： 10.1111/j.1365-2516.2006.01253.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


  8 in total

1.  Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.

Authors:  Joshua I Siner; Benjamin J Samelson-Jones; Julie M Crudele; Robert A French; Benjamin J Lee; Shanzhen Zhou; Elizabeth Merricks; Robin Raymer; Timothy C Nichols; Rodney M Camire; Valder R Arruda
Journal:  JCI Insight       Date:  2016-10-06

2.  Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.

Authors:  S Björkman; V S Blanchette; K Fischer; M Oh; G Spotts; P Schroth; S Fritsch; L Patrone; B M Ewenstein; P W Collins
Journal:  J Thromb Haemost       Date:  2010-04       Impact factor: 5.824

3.  Population pharmacokinetics of recombinant factor VIII:C (ReFacto) in adult HIV-negative and HIV-positive haemophilia patients.

Authors:  Anastasia Karafoulidou; Elena Suarez; Ioanna Anastasopoulou; Olga Katsarou; Anna Kouramba; Paraskevi Kotsi; Anastasios Zografidis; John C Lukas
Journal:  Eur J Clin Pharmacol       Date:  2009-07-30       Impact factor: 2.953

4.  Monitoring rFVIII prophylaxis dosing using global haemostasis assays.

Authors:  M A Al Hawaj; E J Martin; J Venitz; J C Barrett; J G Kuhn; M E Nolte; D F Brophy
Journal:  Haemophilia       Date:  2013-03-19       Impact factor: 4.287

5.  A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management.

Authors:  L A Valentino; V Mamonov; A Hellmann; D V Quon; A Chybicka; P Schroth; L Patrone; W-Y Wong
Journal:  J Thromb Haemost       Date:  2012-03       Impact factor: 5.824

6.  Comparison of continuous infusion versus bolus injection of factor concentrates for blood management after total knee arthroplasty in patients with hemophilia.

Authors:  Young Shil Park; Won-Ju Shin; Kang-Il Kim
Journal:  BMC Musculoskelet Disord       Date:  2017-08-22       Impact factor: 2.362

7.  Effects of replacement therapies with clotting factors in patients with hemophilia: A systematic review and meta-analysis.

Authors:  Carolina J Delgado-Flores; David García-Gomero; Stefany Salvador-Salvador; José Montes-Alvis; Celina Herrera-Cunti; Alvaro Taype-Rondan
Journal:  PLoS One       Date:  2022-01-14       Impact factor: 3.240

8.  Continuous Infusion of Factor VIII and von Willebrand Factor in Surgery: Trials with pdFVIII LFB or pdVWF LFB in Patients with Bleeding Disorders.

Authors:  Jerzy Windyga; Benoît Guillet; Lucia Rugeri; Alexandra Fournel; Ewa Stefanska-Windyga; Valérie Chamouard; Sonia Pujol; Céline Henriet; Françoise Bridey; Claude Négrier
Journal:  Thromb Haemost       Date:  2022-05-31       Impact factor: 6.681
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.